UBI Ubisoft Entertainment SA

Ubisoft General Shareholders’ Meeting, July 10, 2025

Ubisoft General Shareholders’ Meeting, July 10, 2025

   PRESS RELEASE

  

GENERAL SHAREHOLDERS’ MEETING,

JULY 10, 2025

Paris, July 10, 2025 - The Annual General Meeting of shareholders of Ubisoft was held on 10 July 2025 in Paris and was chaired by Yves Guillemot, Chairman of the Board of Directors and Chief Executive Officer.

At this meeting, the shareholders present or represented held an aggregate of 59.85% of outstanding shares.

All resolutions were approved by a large majority, showcasing the broad support of the shareholders in Ubisoft’s strategy.

In particular, the shareholders voted for the appointments of two new independent directors, Axelle Lemaire and André Loesekrug-Pietri who have demonstrated leadership as well as expertise in Technology and Public Affairs. Axelle Lemaire, who formerly served as Secretary of State for Innovation and Digital Affairs in the French Government, is currently a member of the Executive Committee at Sopra Steria in charge of Corporate Responsibility, and brings a unique combination of public policy expertise, digital innovation leadership and CSR. André Loesekrug-Pietri, currently President and Chief Scientist Officer of the Joint European Disruption Initiative, has previously held senior positions in government, entrepreneurship, industry and private equity, including 10 years in China. He is a leader at the forefront of European technology sovereignty with significant Finance expertise. Ubisoft welcomes them to its Board of Directors and looks forward to benefiting from their respective experiences, which will contribute to support Ubisoft’s strategy and its transformation over the coming years. The Board expresses its gratitude for the many years of service of the two outgoing independent directors, Laurence Hubert-Moy and Corinne Fernandez-Handelsman.

The vote also led to the renewals of Claude France, Ubisoft’s Lead Independent Director and Chair of the Audit & Risk Committee, as well as the mandates of Christian Guillemot and Michel Guillemot.

Ubisoft thanks the shareholders who attended the General Meeting for their valuable contributions to the discussions.

The results of the vote on each resolution will be available on the Company’s website ().

Contacts

Investor Relations



 



Alexandre Enjalbert

Head of Investor Relations

78





 
Press Relations



Michael Burk

VP Corporate Communications
   

About Ubisoft

Ubisoft is a creator of worlds, committed to enriching players’ lives with original and memorable entertainment experiences. Ubisoft’s global teams create and develop a deep and diverse portfolio of games, featuring brands such as Assassin’s Creed®, Brawlhalla®, For Honor®, Far Cry®, Tom Clancy’s Ghost Recon®, Just Dance®, Rabbids®, Tom Clancy’s Rainbow Six®, The Crew® and Tom Clancy’s The Division®. Through Ubisoft Connect, players can enjoy an ecosystem of services to enhance their gaming experience, get rewards and connect with friends across platforms. With Ubisoft+, the subscription service, they can access a growing catalog of more than 100 Ubisoft games and DLC. For the 2024–25 fiscal year, Ubisoft generated net bookings of €1.85 billion. To learn more, please visit: .

© 2025 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.

Attachment



EN
10/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

 PRESS RELEASE

Informations sur les droits de vote et les actions au 31 juillet 2025

Informations sur les droits de vote et les actions au 31 juillet 2025 Le 6 août 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 juillet 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total d’actions composant l...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Pelham Smithers
  • Pelham Smithers

PSA Media & Entertainment: Have Video Games Got Too Expensive?

Burdened by higher costs, video game publishers are looking to raise prices. However, PSA’s gaming analyst Pelham Smithers points out that they are facing pushback, and may have to rethink.

Carole Braudeau
  • Carole Braudeau

Credit Morning 07/23/2025

Auchan: First-half sales are expected to fall by 3.3% in France (Olivier Dauvers)|Retail sales in France fell sharply in June, hit by the heatwave and one less Saturday.|ams OSRAM: € 500m private placement of new 2029 notes, preliminary Q2 figures in line|Unicredit withdraws its bid for Banco BPM and publishes strong Q2 results|

ResearchPool Subscriptions

Get the most out of your insights

Get in touch